Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Bioventus Inc.NASDAQ: BVS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q1 FY2026 financing cash flow was -$23.14M, compared with $947K a year earlier. Trailing-twelve-month financing cash flow was -$86.23M.

Context

  • Financing cash flow amounted to 10.8% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Financing cash flow increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near -$23.14M or moves back toward the trailing-twelve-month quarterly average of -$21.56M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.14M-18.6% QoQ
Last fiscal yearDec 2025
-$61.44M+12.6% YoY
LTMMar 2026
-$86.23M+74.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2543.9%——
1 year+12.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(61.44M) USD
Year-over-year change
-12.6%

Financing Cash Flow vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 financing cash flow of $86.23M is the 2nd largest of the 9 companies compared; the peer median is $10.29M.
  • Its year-over-year change of +74.6% is the 4th highest of 9, against a peer median of +19.5%.
  • Financing cash flow amounts to 15.0% of revenue for BVS, versus a peer median of 10.5%.
BVS Competitors Peer median
Financing Cash Flow for BVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNNSmith & Nephew plcFY2025$955M +1010.5%+1.0%15.5%
BVSBioventus Inc.LTM Mar 2026$86.23M +74.6%—15.0%
OFIXOrthofix Medical Inc.LTM Mar 2026$63.96M +123.6%+116.0%7.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$35.52M -226.0%+99.1%6.9%
TELATELA Bio, Inc.LTM Jun 2026$25.56M -40.4%-14.3%32.0%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$21.93M -319.8%—18.0%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$15.46M -2.7%+29.6%13.3%
MDXGMiMedx Group, Inc.LTM Mar 2026$5.12M +41.8%+110.5%1.3%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$1.26M +101.5%—0.1%
Peer median (excluding BVS) $10.29M+19.5%+64.3%10.5%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.45M(144.65M)(121.2M)(318K)27.27M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
Deferred Income Tax(9.76M)(46.66M)(2.38M)(5.39M)(909K)
Stock-Based Compensation19.84M17.59M2.72M10.06M12.67M
Change in Working Capital(15.15M)(29.73M)(3.18M)(11.78M)(13.84M)
Accounts Receivables(20.05M)(17.67M)10.06M(10.67M)(916K)
Inventory3.18M(18.62M)(5.99M)(16.44M)8.57M
Accounts Payables0000(19.81M)
Other Working Capital1.72M6.56M(13.24M)15.32M(1.68M)
Other Non-Cash Items(18.28M)134.52M82.01M(3.33M)1.77M
Operating Cash Flow22.99M(13.54M)15.34M38.8M73.98M
Capital Expenditures(20.89M)(1.48M)(7.36M)(1.01M)(2.56M)
Acquisitions (Net)(262.87M)034.68M0(686K)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(7.37M)(114.96M)(11.51M)23.97M0
Investing Cash Flow(283.76M)(116.44M)15.81M22.96M(3.25M)
Debt Repayment166.2M59.62M(23.26M)(59.58M)(42.91M)
Common Stock Issued109.41M5.82M778K2.44M2.07M
Common Stock Repurchased00000
Dividends Paid(367K)0000
Other Financing Activities(1.88M)(3.37M)(4.17M)2.56M(20.61M)
Financing Cash Flow273.37M62.08M(26.65M)(54.58M)(61.44M)
Effect of Forex Changes(228K)521K629K(2.56M)371K
Net Change in Cash12.37M(67.38M)5.13M4.62M9.66M
Free Cash Flow2.1M(15.02M)7.98M37.79M71.41M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.